Cullinan Therapeutics, Inc.
As of Oct 22, 2026, Cullinan Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 12, 2026). It closed at $14.92, 35.0% below its 52-week high and below its 200-day average, which is rising.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CGEM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CGEM among Biotechnology64th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …64 | CGEM | Stage 3 · wk 2 | 92 | −11.6% |
Cullinan Therapeutics: quick answers
What stage is Cullinan Therapeutics in?
As of Oct 22, 2026, Cullinan Therapeutics (CGEM) is in Stage 3, the topping phase. It entered Stage 3 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Cullinan Therapeutics in an uptrend?
Its uptrend has stalled. Cullinan Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 4.9% below its 200-day average, which is rising.
How far is Cullinan Therapeutics from its 52-week high?
Cullinan Therapeutics closed at $14.92 on Oct 22, 2026, 35.0% below its 52-week high of $22.95. Its 52-week low is $7.19.
How has Cullinan Therapeutics performed over the past year?
As of Oct 22, 2026, Cullinan Therapeutics is up 75.9% over the past year and up 47.4% so far in 2026.
Which sector and industry is Cullinan Therapeutics in?
Cullinan Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.